select a format

Single User License
USD 3500 INR 227465
Site License
USD 7000 INR 454930
Corporate User License
USD 10500 INR 682395

Alternatively

Request a quote
Request a Customized research
Request for Sample Report

NEWSLETTER BY CATEGORY




Recent Viewed Reports


Why Ken Reasearch?


Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements.... "Senior Associate, Booz Allen Hamilton"

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ... "Mohit Mittal, Consultant, KPMG Advisory Services"

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies.... "Mustafa Masood, Financial Analyst , Coldwell Banker Riyadh"

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"


Hepatocyte Growth Factor Hepatopoietin-A or Lung Fibroblast Derived Mitogen-Pipeline Review, H1 2016

Hepatocyte Growth Factor Hepatopoietin-A or Lung Fibroblast Derived Mitogen-Pipeline Review, H1 2016


  • Products Id :- GMDHC0053TDB
  • |
  • Pages: 69
  • |
  • June 2016
  • |
  • |
  Request for Sample Report

Executive Summary

Hepatocyte Growth Factor (Hepatopoietin-A or Lung Fibroblast Derived Mitogen)-Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Hepatocyte Growth Factor (Hepatopoietin-A or Lung Fibroblast Derived Mitogen)-Pipeline Review, H1 2016', provides in depth analysis on Hepatocyte Growth Factor (Hepatopoietin-A or Lung Fibroblast Derived Mitogen) targeted pipeline therapeutics.

The report provides comprehensive information on the Hepatocyte Growth Factor (Hepatopoietin-A or Lung Fibroblast Derived Mitogen) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Hepatocyte Growth Factor (Hepatopoietin-A or Lung Fibroblast Derived Mitogen) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape for Hepatocyte Growth Factor (Hepatopoietin-A or Lung Fibroblast Derived Mitogen)

The report reviews Hepatocyte Growth Factor (Hepatopoietin-A or Lung Fibroblast Derived Mitogen) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Hepatocyte Growth Factor (Hepatopoietin-A or Lung Fibroblast Derived Mitogen) targeted therapeutics and enlists all their major and minor projects

The report assesses Hepatocyte Growth Factor (Hepatopoietin-A or Lung Fibroblast Derived Mitogen) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Hepatocyte Growth Factor (Hepatopoietin-A or Lung Fibroblast Derived Mitogen) targeted therapeutics

Reasons To Buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Hepatocyte Growth Factor (Hepatopoietin-A or Lung Fibroblast Derived Mitogen)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Hepatocyte Growth Factor (Hepatopoietin-A or Lung Fibroblast Derived Mitogen) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications
ankur [@] kenresearch.com
+91-9015378249
www.kenresearch.com

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Hepatocyte Growth Factor (Hepatopoietin-A or Lung Fibroblast Derived Mitogen) Overview 7

Therapeutics Development 8

Hepatocyte Growth Factor (Hepatopoietin-A or Lung Fibroblast Derived Mitogen)-Products under Development by Stage of Development 8

Hepatocyte Growth Factor (Hepatopoietin-A or Lung Fibroblast Derived Mitogen)-Products under Development by Therapy Area 9

Hepatocyte Growth Factor (Hepatopoietin-A or Lung Fibroblast Derived Mitogen)-Products under Development by Indication 10

Hepatocyte Growth Factor (Hepatopoietin-A or Lung Fibroblast Derived Mitogen)-Pipeline Products Glance 12

Late Stage Products 12

Early Stage Products 13

Hepatocyte Growth Factor (Hepatopoietin-A or Lung Fibroblast Derived Mitogen)-Products under Development by Companies 14

Hepatocyte Growth Factor (Hepatopoietin-A or Lung Fibroblast Derived Mitogen)-Products under Development by Universities/Institutes 18

Hepatocyte Growth Factor (Hepatopoietin-A or Lung Fibroblast Derived Mitogen)-Therapeutics Assessment 20

Assessment by Monotherapy/Combination Products 20

Assessment by Mechanism of Action 21

Assessment by Route of Administration 23

Assessment by Molecule Type 25

Hepatocyte Growth Factor (Hepatopoietin-A or Lung Fibroblast Derived Mitogen)-Companies Involved in Therapeutics Development 27

Amgen Inc. 27

AnGes MG, Inc. 28

Kringle Pharma, Inc. 29

M3 Biotechnology, Inc. 30

Minerva Biotechnologies Corporation 31

Molecular Partners AG 32

ViroMed Co., Ltd. 33

Yooyoung Pharmaceutical Co., Ltd. 34

Hepatocyte Growth Factor (Hepatopoietin-A or Lung Fibroblast Derived Mitogen)-Drug Profiles 35

beperminogene perplasmid-Drug Profile 35

Product Description 35

Mechanism Of Action 35

R&D Progress 35

Gene Therapy to Antagonize HGF for Rheumatoid Arthritis and Hepatocellular Carcinoma-Drug Profile 40

Product Description 40

Mechanism Of Action 40

R&D Progress 40

MM-201-Drug Profile 41

Product Description 41

Mechanism Of Action 41

R&D Progress 41

Monoclonal Antibodies to Inhibit Hepatocyte Growth Factor for Metastatic Cancer-Drug Profile 42

Product Description 42

Mechanism Of Action 42

R&D Progress 42

MP-0250-Drug Profile 43

Product Description 43

Mechanism Of Action 43

R&D Progress 43

NK-4-Drug Profile 44

Product Description 44

Mechanism Of Action 44

R&D Progress 44

rilotumumab-Drug Profile 45

Product Description 45

Mechanism Of Action 45

R&D Progress 45

SL-012-Drug Profile 47

Product Description 47

Mechanism Of Action 47

R&D Progress 47

SL-186-Drug Profile 48

Product Description 48

Mechanism Of Action 48

R&D Progress 48

SL-188-Drug Profile 49

Product Description 49

Mechanism Of Action 49

R&D Progress 49

VM-202-Drug Profile 50

Product Description 50

Mechanism Of Action 50

R&D Progress 50

YYB-101-Drug Profile 53

Product Description 53

Mechanism Of Action 53

R&D Progress 53

Hepatocyte Growth Factor (Hepatopoietin-A or Lung Fibroblast Derived Mitogen)-Dormant Projects 54

Hepatocyte Growth Factor (Hepatopoietin-A or Lung Fibroblast Derived Mitogen)-Discontinued Products 56

Hepatocyte Growth Factor (Hepatopoietin-A or Lung Fibroblast Derived Mitogen)-Featured News & Press Releases 57

May 18, 2016: VM BioPharma Announces FDA Fast Track Designation Granted for Investigational Gene Therapy VM202 for Patients with Amyotrophic Lateral Sclerosis 57

Jan 22, 2016: ViroMed Publishes Results from Critical Limb Ischemia Phase II Clinical Study 57

Jan 08, 2016: Molecular Partners to Conduct Phase II Trial of MP0250, a Multi-DARPin Targeting VEGF and HGF, in Multiple Myeloma 58

Nov 07, 2015: Research Presented at AACR-NCI-EORTC Shows Good Tolerability and Sustained Systemic Exposure of MP0250, a Multi-DARPin Targeting VEGF and HGF, in Patients with Advanced Cancer 59

Oct 27, 2015: First clinical data of multi-DARPin MP0250 to be presented at the AACR-NCI-EORTC oncology conference 60

Sep 01, 2015: US FDA Approves Initiation of ViroMed's VM202 for Phase III Clinical Study of Chronic Non-Healing Ischemic Diabetic Foot Ulcer 61

Aug 12, 2015: Patient Enrollment Begins in Europe in the Global Phase III Clinical Trial of HGF Gene Therapy for Critical Limb Ischemia 62

Mar 06, 2015: ViroMed dba VM BioPharma: A Phase II Study Done at Northwestern Hospital Shows Potential Relief for Diabetics with Painful Condition 62

Nov 24, 2014: Amgen Announces Termination Of All Amgen-Sponsored Clinical Studies Of Rilotumumab In Advanced Gastric Cancer 64

Nov 13, 2014: First Patient Dosed in Global Phase III Clinical Trials of HGF Plasmid for Critical Limb Ischemia 64

Oct 29, 2014: AnGes to Start Global Phase III Clinical Trials of HGF Gene Therapy for Critical Limb Ischemia in Europe 65

Oct 16, 2014: First Patient Dosed in Physician-led Study of HGF Gene Therapy in Japan 65

Oct 05, 2014: AnGes Starts Global Phase III Clinical Trials of Collategene for Critical Limb Ischemia 66

Jun 16, 2014: Amgen Joins The National Cancer Institute And Research Partners To Help Accelerate Development Of Personalized Treatment Approaches For Squamous Cell Lung Cancer 66

Jun 12, 2014: AnGes Signs an Agreement with Quintiles for the Global Phase III Trial of Collategene, a Gene Therapy Product for Critical Limb Ischemia 67

Appendix 68

Methodology 68

Coverage 68

Secondary Research 68

Primary Research 68

Expert Panel Validation 68

Contact Us 68

Disclaimer 69

List of Figures

Number of Products under Development for, H1 2016 8

Number of Products under Development by Therapy Area, H1 2016 9

Number of Products under Development by Top 10 Indication, H1 2016 10

Comparative Analysis by Late Stage Development, H1 2016 12

Comparative Analysis by Early Stage Products, H1 2016 13

Assessment by Monotherapy/Combination Products, H1 2016 20

Number of Products by Mechanism of Actions, H1 2016 21

Number of Products by Stage and Mechanism of Actions, H1 2016 21

Number of Products by Routes of Administration, H1 2016 23

Number of Products by Stage and Routes of Administration, H1 2016 23

Number of Products by Molecule Types, H1 2016 25

Number of Products by Stage and Molecule Type, H1 2016 25

List of Tables

Number of Products under Development for, H1 2016 8

Number of Products under Development by Therapy Area, H1 2016 9

Number of Products under Development by Indication, H1 2016 10

Comparative Analysis by Late Stage Development, H1 2016 12

Comparative Analysis by Early Stage Products, H1 2016 13

Number of Products under Development by Companies, H1 2016 14

Products under Development by Companies, H1 2016 15

Products under Development by Companies, H1 2016 (Contd..1) 16

Products under Development by Companies, H1 2016 (Contd..2) 17

Number of Products under Investigation by Universities/Institutes, H1 2016 18

Products under Investigation by Universities/Institutes, H1 2016 19

Assessment by Monotherapy/Combination Products, H1 2016 20

Number of Products by Stage and Mechanism of Action, H1 2016 22

Number of Products by Stage and Route of Administration, H1 2016 24

Number of Products by Stage and Molecule Type, H1 2016 26

Pipeline by Amgen Inc., H1 2016 27

Pipeline by AnGes MG, Inc., H1 2016 28

Pipeline by Kringle Pharma, Inc., H1 2016 29

Pipeline by M3 Biotechnology, Inc., H1 2016 30

Pipeline by Minerva Biotechnologies Corporation, H1 2016 31

Pipeline by Molecular Partners AG, H1 2016 32

Pipeline by ViroMed Co., Ltd., H1 2016 33

Pipeline by Yooyoung Pharmaceutical Co., Ltd., H1 2016 34

Dormant Projects, H1 2016 54

Dormant Projects (Contd..1), H1 2016 55

Discontinued Products, H1 2016 56

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Amgen Inc.

AnGes MG, Inc.

Kringle Pharma, Inc.

M3 Biotechnology, Inc.

Minerva Biotechnologies Corporation

Molecular Partners AG

ViroMed Co., Ltd.

Yooyoung Pharmaceutical Co., Ltd.

Hepatocyte Growth Factor (Hepatopoietin-A or Lung Fibroblast Derived Mitogen) Therapeutic Products under Development, Key Players in Hepatocyte Growth Factor (Hepatopoietin-A or Lung Fibroblast Derived Mitogen) Therapeutics, Hepatocyte Growth Factor (Hepatopoietin-A or Lung Fibroblast Derived Mitogen) Pipeline Overview, Hepatocyte Growth Factor (Hepatopoietin-A or Lung Fibroblast Derived Mitogen) Pipeline, Hepatocyte Growth Factor (Hepatopoietin-A or Lung Fibroblast Derived Mitogen) Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com